Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.7 (plasmin)
 9,023 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A persistent puzzle in our understanding of hemostasis has been the absence of hemorrhagic symptoms in the majority of patients with Hageman trait, the hereditary deficiency of Hageman factor (factor XII). One proposed hypothesis is that alternative mechanisms exist in blood through which plasma thromboplastin antecedent (PTA, factor XI) can become active in the absence of Hageman factor. In order to test this hypothesis, the effect of several proteolytic enzymes, among them thrombin, plasma kallikrein, and trypsin, was tested upon unactivated PTA. PTA was prepared from normal human plasma by Ca(3)(PO(4))(2) adsorption, ammonium sulfate fractionation, and successive chromatography on QAE-Sephadex (twice). Sephadex-G150, and SP-Sephadex. The partially purified PTA was almost all in its native form, with a specific activity of 45-70 U/mg protein; the yield was about 10%. It contained no measurable amounts of other known clotting factors, plasmin, plasminogen, nor IgG. Incubation of PTA with trypsin generated potent clot-promoting activity that corrected the abnormally long clotting time of plasma deficient in Hageman factor or PTA but not in Christmas factor. This clot-promoting agent behaved like activated PTA on gel filtration (apparent molecular weight: 185,000) and was specifically inhibited by an antiserum directed against activated PTA. These data suggested that PTA can be converted into its active form by trypsin. PTA was not activated by thrombin, chymotrypsin, papain, ficin, plasmin, plasma kallikrein, tissue thromboplastin, or C. Trypsin converted PTA to its active form enzymatically. Whether trypsin serves to activate PTA in vivo is not yet clear.
 ...
PMID:Partial purification of plasma thromboplastin antecedent (factor XI) and its activation by trypsin. 426 22

No distinct differences were noted in the components of plasmin-treated IgG from the known components of papain-treated IgG (Fab and Fc fragments and untreated IgG) on the physicochemical and the immunological properties and the biological activities. Incubation of IgG with 30 cu/g of plasmin for 96 hours at 20 degrees C was found to be optimum. The plasmin-treated IgG by this condition, which gives complement-fixing ability (C'H50) below 23, did not show blood pressure depression, i.e. below 10% for dogs. Three components (Pl-Fab, Pl-Fc and Pl-IgG) were isolated from the plasmin-treated IgG by gel filtration on Sephadex G200 and CM-cellulose column chromatography. The Pl-Fc and the Fc isolated from the papain-treated IgG were obtained in crystalline forms. The extinction coefficients at 280 nm were 14.0 (IgG), 14.2 (Pl-Fab) and 14.1 (Pl-Fc). The molecular weights were 163,000, 58,000 and 54,000 and the S20,w values were 6.82, 3.82 and 3.77 for Pl-IgG, Pl-Fab and Pl-Fc, respectively. These three components were identical with IgG, Fab and Fc, respectively, on the electrophoretic and the immunological demonstrations. The titer of complement-fixation of IgG was decreased from 49 to 19 by plasmin treatment, however, it was retained at low level even in each isolated component. Whe 7S IgG was incubated at 37 degrees C, reaggregation was observed, as generally understood accompanying by elevated complement-fixing ability. Whereas it was noticed after long-term incubation of plasmin-treated IgG that the changes of complement-fixing ability could occur independently from the amount of aggregates. This fact was clearly revealed on the experiments in which IgG was treated at pH 3 in glycine buffer solution.
 ...
PMID:[Studies on the properties of the component of plasmin-treated IgG and the relation between IgG aggregates and complement-fixing ability (author's transl)]. 428 70

The interaction alpha 2-macroglobulin with four proteinases has been investigated by binding assays and by gel electrophoresis. At pH 7.65 the binding ratios of the proteinase-alpha 2-macroglobulin complexes were found to be 2:1 (trypsin and papain), 1.4:1 (chymotrypsin), and 1:1 (plasmin). The progressive decrease in the stoichiometry of the three seryl proteinase complexes was paralleled by a concomitant decrease in the proteinase-dependent specific cleavage of the alpha 2-macroglobulin peptide chains. Rate studies have shown that the relative rates of reaction of the proteinases with alpha 2-macroglobulin also varied greatly: papain greater than trypsin greater than chymotrypsin greater than plasmin. The data suggest that the ability of a proteinase to saturate the second proteinase binding site is a reflection of its ability to bind to alpha 2-macroglobulin and cleave the second pair of scissile alpha 2-macroglobulin peptide bonds before the alpha 2-macroglobulin has undergone the conformational change initiated by the formation of the 1:1 proteinase alpha 2-macroglobulin complex.
 ...
PMID:Interaction of alpha 2-macroglobulin with trypsin, chymotrypsin, plasmin, and papain. 618 88

Although it is known that most of the plasma proteinase inhibitors form complexes with proteinases that are not dissociated by SDS (sodium dodecyl sulphate), there has been disagreement as to whether this is true for alpha 2M (alpha 2-macroglobulin). We have examined the stability to SDS with reduction of complexes between alpha 2M and several 125I-labelled proteinases (trypsin, plasmin, leucocyte elastase, pancreatic elastase and papain) by gel electrophoresis. For each enzyme, some molecules were separated from the denatured alpha 2M chains, but amounts ranging from 8.3% (papain) to 61.2% (trypsin) were bound with a stability indicative of a covalent link. Proteolytic activity was essential for the covalent binding to occur, and the proteinase molecules became attached to the larger of the two proteolytic derivatives (apparent mol.wt. 111 000) of the alpha 2M subunit. We take this to mean that cleavage of the proteinase-susceptible site sometimes leads to covalent-bond formation between alpha 2M and proteinase. Whatever the nature of this bond, it does not involve the active site of the proteinase, as bound serine-proteinase molecules retain the ability to react with the active-site-directed reagent [3H]Dip-F (di-isopropyl phosphorofluoridate). Our conclusion is that the ability to form covalent links is not essential for the inhibitory capacity of alpha 2M. It may, however, help to stabilize the complexes against dissociation or proteolysis.
 ...
PMID:Covalent binding of proteinases in their reaction with alpha 2-macroglobulin. 620 37

No activity of the plasmin and plasminogen activators could be detected in middle ear effusion (MEE). A streptokinase proactivator, which was not plasminogen and markedly enhanced the activation of plasminogen by streptokinase, could be detected. MEE had an apparent inhibitory activity against both thiol protease (papain) and serine proteases (plasmin and trypsin). All these findings indicate that MEE contains unsaturated protease inhibitors and is in a state of predominance of inhibitors over fibrinolytic activity.
 ...
PMID:Antifibrinolytic activity in middle ear effusion. 623 94

Prokallikrein was activated by trypsin and by alpha-chymotrypsin, but not by proteases, such as plasmin, thrombin, urokinase, carboxypeptidase B, papain, elastase, pepsin, and cathepsin D. Moreover, rat fresh serum did not activate prokallikrein. Maximum activation of prokallikrein by trypsin was obtained at the concentration of 10 micrograms to 1 mg per ml in PBS and that by alpha-chymotrypsin was at the concentration of 5 mg per ml. The enzymic properties of trypsin-activated and alpha-chymotrypsin-activated kallikreins were identical with those of active kallikrein in the kidney.
 ...
PMID:Activation of prokallikrein in the rat kidney by proteases. 637 43

An acid-stable protease inhibitor (AS-PI) has been previously demonstrated in ascitic fluid from patients with ovarian carcinoma. In this study, the AS-PI was further purified using DEAE-cellulose and isoelectric focusing (IEF), and a partial characterization was undertaken. On DEAE-cellulose ion-exchange column chromatography, AS-PI activity was observed in both adsorbed and non-adsorbed fractions. The former represented the main AS-PI peak. By IEF, the respective pI values were 1.6 and 4.5. By gel filtration, the molecular weight of the main (adsorbed fraction) AS-PI was 78 000. This AS-PI strongly inhibited trypsin and to a lesser extent chymotrypsin, but exerted no inhibitory effect on plasmin. It slightly inhibited SH proteases such as papain and ficin. Immunologically, AS-PI was distinct from alpha 1-antitrypsin, alpha 1-antichymotrypsin, inter-alpha-trypsin inhibitor, antithrombin III, C1-inactivator, alpha 2-macroglobulin and alpha 2-plasmin inhibitor. The main AS-PI reacted with and was neutralized by antiurinary trypsin inhibitor serum, and on immunoelectrophoresis, had a mobility slightly cathodal to serum albumin.
 ...
PMID:Further purification and characterization of acid-stable protease inhibitor from ascites of an ovarian carcinoma patient. 643 8

Activation of bovine plasma prekallikrein was investigated with several proteinases. Highly purified bovine plasma prekallikrein was rapidly activated to kallikrein [EC 3.4.21.8] by bovine activated Hageman factor, trypsin [EC 3.4.21.4] and Pronase P (proteinases from Streptomyces griseus) and more gradually by papain [EC 3.4.22.2] and ficin [EC 3.4.22.3]. Activation of prekallikrein was also observed with bovine plasmin [EC 3.4.21.7], but not with bovine clotting factors Xa (Stuart factor) [EC 3.4.21.6] and IXa (Christmas factor) or thrombin [EC 3.4.21.5]. Urokinase [EC 3.4.99.26], Reptilase, collagenase [EC 3.4.24.3], elastase [EC 3.4.21.11], alpha-chymotrypsin [EC 3.4.21.1], Nagarse [EC 3.4.21.14], and stem bromelain [EC 3.4.22 4] did not convert prekallikrein to kallikrein. Plasma kallikrein activated to Hageman factor released kinin rapidly from bovine high molecular weight (HMW) kininogen. However, from bovine low molecular weight (LMW) kininogen, liberation of kinin was extremely slow. The kallikrein activity was inhibited by soybean trypsin inhibitor (SBTI), Trasylol, diisopropylfluorophosphate (DFP), and N-alpha-tosyl-L-lysine chloromethylketone (TLCK), but not by egg-white trypsin inhibitor (EWTI), lima bean trypsin inhibitor (LBTI), heparin or hexadimethrine bromide (Polybrene). The kallikrein formed an enzyme-inhibitor complex with SBTI and Trasylol, but not with LBTI. Prekallikrein did not react with SBTI. Prekallikrein consists of a single polypeptide chain of molecular weight about 90,000, as estimated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. Activation of prekallikrein by Hageman factor was found to involve cleavage of the single peptide bond on the disulfide-bridged polypeptide chain, and no change of molecular weight was observed during the activation. The peptide bond cleaved in prekallikrein by the activation was an Arg-X peptide bond on a disulfide-bridged polypeptide chain.
 ...
PMID:Studies on prekallikrein of bovine plasma. II. Activation of prekallikrein with proteinases and properties of kallikrein activated by bovine Hageman factor. 676 24

Compared with croton oil- and thioglycolate-induced macrophages, the PHA-induced peritoneal macrophages showed th highest cytocidal activity against human malignant melanoma, mammary carcinoma and rat R3230 adenocarcinoma (AdCa) cells. Resident (physiological saline-induced) macrophages showed the lowest cytocidal activities. Vibrio cholera neuraminidase (VCN) and galactose oxidase increased, whereas trypsin, plasmin, papain and mild sonication decreased the cytotoxic function of macrophages against the neoplastic target cells. The effect of macrophage membrane prepartions on the cytocidal action of whole macrophages was also examined. VCN and galactose oxidase increased, whereas trypsin, plasmin, papain and mild sonication reduced the effects. It is concluded that the possible modulation of the cytocidal function of macrophages is due either to direct enzyme action on the macrophage surface, or to indirect enzyme action with enzymatically produced membrane preparations. Macrophage membrane preparations could either enhance or inhibit the antineoplastic action of the macrophags.
 ...
PMID:Correlation between macrophages and their membrane fraction. Cytocidal activities on neoplastic cells. 699 9

Limulus amebocyte lysate was fractionated by heparin-Sepharose chromatography into four components (fractions A, B, C and D). Major coagulation factors, i.e., proclotting enzyme, coagulogen, and proclotting enzyme activating factor precursor (proactivator) in the lysate were eluted, respectively, in fraction A, fraction B and fraction C. Clotting enzyme activity was detected only following recombination of fraction A and fraction C in the presence of endotoxin. The conversion of proactivator to its active form (activator) was an endotoxin-dependent reaction and was inhibited by polymyxin B. Either proactivator is an endotoxin-sensitive factor or another endotoxin-sensitive factor, which activates proactivator, is present in fraction C. Optimal pH for proclotting enzyme activation by activator was broad and ranged from pH 6.0 to 8.0, while that for the endotoxin-mediated activation of proactivator was pH 7.0. No initial latent period was observed during activation of the proactivator or proenzyme. The activator was inhibited by benzamidine, leupeptin, soybean trypsin inhibitor and diisopropyl fluorophosphate, suggesting that the activator is a trypsin-type serine protease. Trypsin, but not thrombin, urokinase, plasmin, papain or alpha-chymotrypsin activated the proclotting enzyme. Therefore, limited proteolysis, i.e., of an arginyl- or lysyl-X bond(s), of the proenzyme molecule is probably involved in its activation.
 ...
PMID:Fractionation of Limulus amebocyte lysate. Characterization of activation of the proclotting enzyme by an endotoxin-mediated activator. 713 84


<< Previous 1 2 3 4 5 6 7 8 9 Next >>